Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells

(2015) Sarah K. Maenhout et al.   Oncotarget

Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation

(2014) Huaqin Yuan et al.   BIOMEDICINE & PHARMACOTHERAPY

Immunotherapy for Brain Cancer: Recent Progress and Future Promise

(2014) C. M. Jackson et al.   CLINICAL CANCER RESEARCH

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

(2013) S. Wilgenhof et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts

(2013) Sarah K. Maenhout et al.   INTERNATIONAL JOURNAL OF CANCER

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors

(2013) Franziska Stehle et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer

(2013) Je-In Youn et al.   NATURE IMMUNOLOGY

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

(2012) C Goyvaerts et al.   GENE THERAPY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

(2012) Anamika Bose et al.   MELANOMA RESEARCH

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Firefly Luciferase by General Anesthetics: Effect on In Vitro and In Vivo Bioluminescence Imaging

(2012) Marleen Keyaerts et al.   PLoS One

Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen

(2012) Stefano Ugel et al.   Cell Reports

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

(2012) Salem Chouaib et al.   Frontiers in Immunology

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

(2011) J. Fruehauf et al.   CLINICAL CANCER RESEARCH

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

(2011) B. Poller et al.   DRUG METABOLISM AND DISPOSITION

Plasticity of Ly-6Chi Myeloid Cells in T Cell Regulation

(2011) B. Zhu et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts

(2010) Jochen Rössler et al.   INTERNATIONAL JOURNAL OF CANCER

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease

(2009) I. L. King et al.   BLOOD

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine

(2009) Irina Daurkin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation

(2009) Alberto Mantovani et al.   HUMAN IMMUNOLOGY

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH